Show simple item record

Safety and efficacy results of durvalumab following sequential chemoradiotherapy (sCRT) in unresectable stage III NSCLC (PACIFIC 6)

dc.contributor.authorHeilmann, M.
dc.contributor.authorGarassino, M. C.
dc.contributor.authorMazieres, J.
dc.contributor.authorChouaid, C.
dc.contributor.authorBischoff, H.
dc.contributor.authorReinmuth, N.
dc.contributor.authorCove Smith, L.
dc.contributor.authorMansy, T.
dc.contributor.authorCortinovis, D.
dc.contributor.authorMigliorino, M. R.
dc.contributor.authorDelmonte, A.
dc.contributor.authorSanchez, J. G.
dc.contributor.authorVelarde, L. E. C.
dc.contributor.authorBernabe, R.
dc.contributor.authorPaz Ares, L.
dc.contributor.authorPerez, D. I.
dc.contributor.authorTrunova, N.
dc.contributor.authorForoutanpour, K.
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorReck, M.
dc.date.accessioned2022-11-30T10:21:33Z
dc.date.available2022-11-30T10:21:33Z
dc.date.issued2022en
dc.identifier.citationHeilmann M, Garassino MC, Mazieres J, Chouaid C, Bischoff H, Reinmuth N, et al. Safety and Efficacy Results of Durvalumab following Sequential Chemoradiotherapy (sCRT) in Unresectable Stage III NSCLC (PACIFIC 6). Oncology Research and Treatment. 2022 Sep;45(SUPPL 2):97-8. PubMed PMID: WOS:000864724100188.en
dc.identifier.urihttp://hdl.handle.net/10541/625840
dc.titleSafety and efficacy results of durvalumab following sequential chemoradiotherapy (sCRT) in unresectable stage III NSCLC (PACIFIC 6)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentRH Klinikum Siloah, Pneumologie, Intensiv und Schlafmedizin, Hannover, Deutschlanden
dc.identifier.journalOncology Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record